Contents
PART I CHROMATIN STRUCTURE, DYNAMICS AND DISEASE 1 1 Structural Organization of Dynamic Chromatin 3 Kohji Hizume, Shige H. Yoshimura, Masahiro Kumeta and Kunio Takeyasu 2 ATP-Dependent Chromatin Remodelling Action and Reaction 29 Parul Choudhary and Patrick Varga-Weisz 3 Regulation of Chromatin Structure and Chromatin-Dependent Transcription by Poly ADP-Ribose Polymerase-1 Possible targets David A. Wacker, Kristine M. Frizzell, Tong Zhang and W. Lee Kraus 4 Histone Variant Nucleosomes...
P713t
Cell line Primary Primary Cell line Cell line Cell line Gayther et al., 2000 Gayther et al., 2000 Koshiishi et al., 2004 Bryan et al., 2002 Bryan et al., 2002 Gayther et al., 2000 Gayther et al., 2000 Bryan et al., 2002 Bryan et al., 2002 Shigeno et al., 2004 Ohshima etal, 2001 Ozdag et al., 2002 Ozdag et al., 2002 a Shown are nonsense, missense, deletion insertion and splice site mutations. b The amino acid changes are predictions in many cases. c X denotes a stop codon. d Originally annotated...
Smar1
Ubiquitous but predominant in thymus Ubiquitous, particular high levels in neuron of the post natal brain 3. ROLE OF MARBPS IN MODULATING MARS AS FUNCTIONAL ELEMENT Gene expression status involves changing of attachment points of chromatin loops and hence implies the dynamicity of MARs and its association with nuclear matrix, regulated and governed by cell type Liebich et al., 2002 . The intrinsic activity of MAR is not sufficient to bring about position effects or transcriptional regulation...
Nucleolin As A Protooncogene That Stimulates Cell Proliferation
It has been shown that in cancer cell lines characterized by different proliferation rates, the transcriptional activity of RNA polymerase I and the expression of the major nucleolar proteins involved in the control of rRNA transcription and processing are directly related to nucleolar size and to the rapidity of cell proliferation Derenzini et al., 1998 . Several observations suggest that nucleolin is a major actor in promoting cell proliferation. First of all, its amount is correlated with...
Non Histone Protein Acetylation Link To Diseases
Aberrant acetylation levels of non histone proteins not only lead to the dysfunction of these proteins but also cause disturbances in cellular processes thereby leading to several diseases Fig. 3 . There are several reports of aberrant acetylation in diseases like cancer, diabetes, cardiac hypertrophy and viral diseases. Diabetes is hypothesized to cause cardiac protein acetylation and the acety-lation alters the protein function Fig. 3b . Hypoxia-inducible factor-1 HIF1 is a transcription...
Rote of Nterminal tails of nucleosome core histones to the accessibility of
Distamycin and other minor groove binders of the same class In order to detect the binding loci of this class of groove binders in the nucleosomal DNA, hydroxyl radical and DNase I footprinting studies were carried out on the complexes of four AT-selective minor groove binding ligands Hoechst, distamycin, netropsin and berenil with DNA fragments which have been reconstituted with nucleosome core particles Brown and Fox, 1996 . Hydroxyl radical footprints of reconstituted tyrT DNA show that all...
Variants Of Other Histones
Histone H4 seems to be the most slowly evolving histones, very few amino acid exchanges have been reported for fungi, plants, and metazoans Malik and Henikoff 2003 . One explanation for this could be the extensive protein-protein interactions between H4 and other histones within the nucleosome. Amino acid substitutions within H4 would be possible only in a few positions without disrupting the structure or the nucleosome. The N-terminal tail of H4 is also conserved, since it is extensively...
Molecular And Structural Basis Of Dnabinding Anticancer Drug Action
Anticancer drugs targeted to DNA bind to the same by either non-covalent forces or covalent interactions. The primary and most important step in the functioning of a DNA targeting drug is the base-specific recognition of DNA by the drug. This initial process of recognition is driven by size and shape complementarities between the drug and its DNA - binding site. Non-covalent forces such as the coulombic force, van der Waals interactions, hydrogen bonding and stacking interaction stabilize the...
Thermodynamics And Crystallography Of Drugdna Interaction In Chromatin And
An elucidation of the energetics of association of the non-covalently binding drugs to DNA as an integral part of chromatin and nucleosome is required to understand the structural basis of their association. It tells about the alteration in the state of the DNA in the chromatin or nucleosome as a result of the association with the drug. The scenario will be more complex for the covalently binding drugs. However, there has been very few studies aimed at understanding the energetics of...
Bleomycin
CHO cells, also show a lower sensitivity to bleomycin Lopez-Larraza et al., 2006 . The ATC-15 cells exhibit satisfactory growth at bleomycin doses that produce a permanent growth arrest of CHO cells, thereby suggesting that mosquito cells might have linker DNA shorter than that of mammalian cells. Bleomycin induced chromosomal damage in Chinese hamster bone marrow gives rise to micronuclei by means of lagging chromatin main and micronuclei eventually become asynchronous in consecutive cell...
Parp1 As A Therapeutic Target In Disease
4.1. Role of PARP-1 in Physiological and Pathophysiological Processes Genome Maintenance, Cell Death, and Inflammation PARP-1 has been implicated in a variety of physiological and pathophysiological processes, including genome maintenance, carcinogenesis, aging, immunity, inflammation, and neurological function Kim et al., 2005 Table 2 . PARP-1's roles in DNA repair, cell death pathways, and pro-inflammatory gene expression underlie many of the contributions PARP-1 makes to the aforementioned...
Ag14361
Figure 7. Structures of PARP-1 inhibitors. The structures of PARP-1 inhibitors discussed in the text are shown. Nicotinamide a , a product of PARP-1 enzymatic action on NAD and a weak inhibitor of PARP-1 activity, served as a model for the first synthetic PARP-1 inhibitors, including benzamide and 3-aminobenzamide b . Later synthetic compounds, such as 1,5-dihydroisoquinoline c , were used in turn to develop even more inhibitors with greater specificity, potency, and solubility, including...